Cargando…
Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo
Combining nanotechnology and bioorthogonal chemistry for theranostic strategies offers the possibility to develop next generation nanomedicines. These materials are thought to increase therapeutic outcome and improve current cancer management. Due to their size, nanomedicines target tumors passively...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805177/ https://www.ncbi.nlm.nih.gov/pubmed/35851967 http://dx.doi.org/10.1002/chem.202201847 |
_version_ | 1784862283877318656 |
---|---|
author | Poulie, Christian B. M. Sporer, Emanuel Hvass, Lars Jørgensen, Jesper T. Kempen, Paul J. Lopes van den Broek, Sara I. Shalgunov, Vladimir Kjaer, Andreas Jensen, Andreas I. Herth, Matthias M. |
author_facet | Poulie, Christian B. M. Sporer, Emanuel Hvass, Lars Jørgensen, Jesper T. Kempen, Paul J. Lopes van den Broek, Sara I. Shalgunov, Vladimir Kjaer, Andreas Jensen, Andreas I. Herth, Matthias M. |
author_sort | Poulie, Christian B. M. |
collection | PubMed |
description | Combining nanotechnology and bioorthogonal chemistry for theranostic strategies offers the possibility to develop next generation nanomedicines. These materials are thought to increase therapeutic outcome and improve current cancer management. Due to their size, nanomedicines target tumors passively. Thus, they can be used for drug delivery purposes. Bioorthogonal chemistry allows for a pretargeting approach. Higher target‐to‐background drug accumulation ratios can be achieved. Pretargeting can also be used to induce internalization processes or trigger controlled drug release. Colloidal gold nanoparticles (AuNPs) have attracted widespread interest as drug delivery vectors within the last decades. Here, we demonstrate for the first time the possibility to successfully ligate AuNPs in vivo to pretargeted monoclonal antibodies. We believe that this possibility will facilitate the development of AuNPs for clinical use and ultimately, improve state‐of‐the‐art patient care. |
format | Online Article Text |
id | pubmed-9805177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98051772023-01-06 Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo Poulie, Christian B. M. Sporer, Emanuel Hvass, Lars Jørgensen, Jesper T. Kempen, Paul J. Lopes van den Broek, Sara I. Shalgunov, Vladimir Kjaer, Andreas Jensen, Andreas I. Herth, Matthias M. Chemistry Research Articles Combining nanotechnology and bioorthogonal chemistry for theranostic strategies offers the possibility to develop next generation nanomedicines. These materials are thought to increase therapeutic outcome and improve current cancer management. Due to their size, nanomedicines target tumors passively. Thus, they can be used for drug delivery purposes. Bioorthogonal chemistry allows for a pretargeting approach. Higher target‐to‐background drug accumulation ratios can be achieved. Pretargeting can also be used to induce internalization processes or trigger controlled drug release. Colloidal gold nanoparticles (AuNPs) have attracted widespread interest as drug delivery vectors within the last decades. Here, we demonstrate for the first time the possibility to successfully ligate AuNPs in vivo to pretargeted monoclonal antibodies. We believe that this possibility will facilitate the development of AuNPs for clinical use and ultimately, improve state‐of‐the‐art patient care. John Wiley and Sons Inc. 2022-09-01 2022-11-02 /pmc/articles/PMC9805177/ /pubmed/35851967 http://dx.doi.org/10.1002/chem.202201847 Text en © 2022 The Authors. Chemistry - A European Journal published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Poulie, Christian B. M. Sporer, Emanuel Hvass, Lars Jørgensen, Jesper T. Kempen, Paul J. Lopes van den Broek, Sara I. Shalgunov, Vladimir Kjaer, Andreas Jensen, Andreas I. Herth, Matthias M. Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo |
title | Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo |
title_full | Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo |
title_fullStr | Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo |
title_full_unstemmed | Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo |
title_short | Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo |
title_sort | bioorthogonal click of colloidal gold nanoparticles to antibodies in vivo |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805177/ https://www.ncbi.nlm.nih.gov/pubmed/35851967 http://dx.doi.org/10.1002/chem.202201847 |
work_keys_str_mv | AT pouliechristianbm bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT sporeremanuel bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT hvasslars bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT jørgensenjespert bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT kempenpaulj bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT lopesvandenbroeksarai bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT shalgunovvladimir bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT kjaerandreas bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT jensenandreasi bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo AT herthmatthiasm bioorthogonalclickofcolloidalgoldnanoparticlestoantibodiesinvivo |